

Lymphoma and Myeloma

MD Anderson Cancer Center is home to one of the largest multidisciplinary programs in the nation for the diagnosis and treatment of lymphoma and myeloma. With more than 35,000 patient visits annually, we offer your patients access to targeted therapies and numerous [clinical trials](#), many only available here.

[The Lymphoma and Myeloma team](#) offers an array of options for patients with recurrent disease, with a focus on giving patients the best hope to live full, healthy lives.

Our physicians collaborate with and serve as a resource for medical and hematologist-oncologists to ensure their patients have the coordination of care required. This collaboration results in a deeper understanding of each patient's cancer while meeting the needs of your practice.

A New Diagnosis of Lymphoma

Lymphoma is not one cancer diagnosis; it's many. With more than 60 different subtypes of lymphoma, initial diagnosis and treatment can be complicated. For some subtypes, specialized approaches and clinical trials are needed to increase the chance of cure and enhance quality of life.

Relapse and Remission

70% of patients with relapsed or refractory [mantle cell lymphoma](#) responded to the targeted therapy ibrutinib, and a study showing 42% of patients with [aggressive large B-cell lymphoma](#) remained in remission at 15 months following treatment with the CAR T cell therapy, axi-cel.



WAYS TO REFER

REFERRING PROVIDER TEAM

Phone: 1-877-632-6789

Fax: 713-563-2449

Monday-Friday: 8 a.m.-11 p.m.

Saturday-Sunday: 8 a.m.-7 p.m.

physicianreferrals@mdanderson.org

Learn more about how to [refer a patient](#).

Lymphoma and Myeloma

Why MD Anderson

Additional Treatment Options

When patients relapse or are refractory to treatment, the availability of new treatment options continues to change. That's why our team is committed to finding new, effective ways to treat these patients. We offer a wide variety of treatments, and many of these options are new discoveries only offered here. Some available treatments and clinical trials include:

Bone Marrow and Stem Cell Transplants

Our [Stem Cell Transplantation and Cellular Therapy program](#) is among the largest, most active programs in the nation, performing more than 800 procedures annually. Our clinic is dedicated to monitoring and managing graft versus host disease, and we are a matched unrelated donor program, which has earned us recognition as a specialized center for stem cell transplants by the National Marrow Donor Program.

Radiation Therapy

We offer a wide array of [radiation therapies](#), including IMRT, VMAT, proton therapy and radioimmunotherapy.

Chimeric Antigen Receptor (CAR) T Cell Therapy

The MD Anderson [CAR T cell](#) program is one of the largest in the world, leading the development of new FDA-approved therapies, treating patients, and developing new treatment strategies and national guidelines for managing side effects.

MD Anderson has one of the largest groups of physicians, researchers and clinical staff dedicated exclusively to providing care and defining new strategies to improve survival for patients with lymphoma and myeloma. As a leader in drug development, our team helped establish FDA approval of leading-edge therapies that are now considered the standard. These include CAR T cell therapy, ibrutinib, acalabrutinib, bortezomib and lenalidomide.

We also continue to advance patient care through discoveries, including management of CAR T cell toxicities, chemotherapy-free regimens and novel tests, like cell-free DNA. With more than 100 active [clinical trials](#), we provide innovative therapies with unique mechanisms of actions, such as bispecific antibodies, small molecules, and drug combinations. Many of these were designed by our experts.

Lymphoma

MD Anderson participates in The Lymphoma Epidemiology of Outcomes Cohort Study or [LEO](#), the nation's largest study following patients newly diagnosed with non-Hodgkin lymphoma with the goal of identifying clinical, epidemiologic, genetic, tumor and treatment factors to improve outcomes and quality of life for survivors. [Christopher Flowers, M.D.](#), the chair of MD Anderson's Lymphoma and Myeloma Center, is a lead investigator for the overall LEO study. Dr. Flowers also is a CPRIT Scholar, an award designed to attract world-class scientists to Texas to lead in the fight against cancer.

Led by our disease expert, [Michael Wang, M.D.](#), nearly every advancement for mantle cell lymphoma over the last decade has occurred at MD Anderson.

Because there are so many varieties of lymphoma, a cure will not come from a one-treatment-fits-all approach. [The MD Anderson Moon Shots Program®](#) and [Adoptive Cellular Therapy](#) platform are research engines driving new ways to generate immune cells targeted at curing patients who relapse after standard treatments.

Myeloma

At MD Anderson, we offer molecular testing, including next generation sequencing translocation and FISH, to provide more detailed data for patients at diagnosis and relapse.

THE UNIVERSITY OF TEXAS

MDAnderson
Cancer Center

Making Cancer History®

Lymphoma and Myeloma

Connect with us.

A Safer Environment

Keeping our patients and workforce safe has always been our top priority. We continue to proactively implement measures to ensure the safety of patients on all our campuses. To learn more about our response to COVID-19, visit our [Coronavirus Precautions](#) page.

Oncology Care Team

For information about our lymphoma and myeloma faculty and staff, visit [our directory](#).

Patient Referrals

Our [Referring Provider Team](#) is dedicated to assisting health care providers with the following:

- Referrals to any MD Anderson center or location
- Continuous follow-up on the status of referrals
- Answers to questions about patient access procedures
- Support with our online physician portal

Physician Portal

Our secure, HIPAA-compliant portal is available for health care providers to take an active role in managing patient care at MD Anderson. Visit [myMDAnderson](#) to:

- Access patient appointment schedules
- Access transcribed patient reports and results
- Receive notifications regarding referral status and results
- Update your profile and contact information

THE UNIVERSITY OF TEXAS

MDAnderson
Cancer Center

Making Cancer History®



HEALTH CARE PROVIDER
RESOURCE CENTER

Cancers We Treat

- [Amyloidosis](#)
- [Follicular lymphoma](#)
- [Hodgkin lymphoma](#)
- [Mantle cell lymphoma](#)
- [Myeloma](#)
- [Non-Hodgkin lymphomas](#), including B-cell and T-cell lymphomas
- [Waldenström's macroglobulinemia](#)



WAYS TO REFER

REFERRING PROVIDER TEAM

Phone: 1-877-632-6789

Fax: 713-563-2449

Monday-Friday: 8 a.m.-11 p.m.

Saturday-Sunday: 8 a.m.-7 p.m.

physicianreferrals@mdanderson.org

Learn more about how to [refer a patient](#).